Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
manganese butoxyethyl pyridyl porphyrin
- Development stage
- Phase 2
- Lead developer
- BioMimetix JV
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Administration
- Subcutaneous, Topical
01
Overview
BMX-001 is a small molecule, redox-active metalloporphyrin developed to mimic the action of superoxide dismutase (SOD), an endogenous enzyme that neutralizes harmful free radicals. Its primary mechanism involves modulation of cellular signaling pathways by inhibiting NF-kappa B and HIF-1α transcription factors and stimulating Nrf2. This dual action augments the tumor-killing effects of radiation therapy while protecting normal tissues from radiation-induced injury. BMX-001 is being developed primarily for use in combination with chemoradiation to treat high-grade glioma and other cancers such as rectal cancer, anal cancer, head and neck cancer, ovarian cancer (preclinical), and brain metastases. The drug was created at Duke University by Ines Batinic-Haberle after decades of research on SOD mimetics[2][5][6][7]. It has shown improved survival rates and reduced cognitive decline in patients with advanced brain cancers[5][7]. Orphan drug status has been granted for glioma[2].
- Other names
- manganese butoxyethyl pyridyl porphyrinMnTnBuOE-2-PyP5+
02
Targets
NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)NF-κBHIF1A (Hypoxia-inducible factor 1-alpha)
Beyond the preview
Go deeper on manganese butoxyethyl pyridyl porphyrin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on manganese butoxyethyl pyridyl porphyrin.